Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

This Biotech Stock Is Too Cheap to Ignore

TheMotleyFool

0 0

This Biotech Stock Is Too Cheap to Ignore

Investing in a small biotech company can be maddening. The stock can rise and fall with no news, leaving shareholders wondering who knows something they don't. Over the long term, it's best to stick with the science and ignore the short-term gyrations. But that can be hard.

Trillium Therapeutics (NASDAQ: TRIL) rose 6,000% between December 2019 and November 2020. New leadership, clinical focus, and promising results whipped up investor interest. From a scientific perspective, nothing has really changed. Yet shares are down 66% from that 2020 peak. They've gotten too cheap to ignore.